WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
A homeless man is reunited with his family after 13 years thanks to a Ford Mustang and a viral clipWoman, 26, who shed 70lbs reveals the surprising ways weight loss has transformed her lifeGunmen ambush vehicle carrying customs officials in northwest Pakistan, killing 4 officersThe Arizona Coyotes are officially headed to Salt Lake CityCaitlin Clark fans won't receive Indiana Fever jerseys until August due to Nike blunderLawsuit filed over new Kentucky law aimed at curbing youth vapingRap artist GloRilla has been charged with drunken driving in GeorgiaClosing arguments set in trial of an Arizona rancher charged in fatal shooting of unarmed migrantDevon Windsor, 30, flaunts her slender postLiquor sales in movie theaters, to
2.0442s , 6501.6015625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Worldly Wisdom news portal